RT @ESteyerberg: A positive result from the TAILORx trial is that it will contribute to reducing adjuvant chemotherapy in breast cancer. At…
RT @drchrysopoulo: Landmark #TAILORx study definitively shows chemo may be spared in about 70% of hormone +ve, HER2 -ve, node-neg #BreastCa…
RT @drchrysopoulo: Landmark #TAILORx study definitively shows chemo may be spared in about 70% of hormone +ve, HER2 -ve, node-neg #BreastCa…
RT @DrLoveResearch: About 70% of women diagnosed w/ the early stages of one of the most common forms of breast cancer might not need chemot…
RT @ESteyerberg: A positive result from the TAILORx trial is that it will contribute to reducing adjuvant chemotherapy in breast cancer. At…
RT @drchrysopoulo: Landmark #TAILORx study definitively shows chemo may be spared in about 70% of hormone +ve, HER2 -ve, node-neg #BreastCa…
@DavidLBrownMD @ADAlthousePhD @RogueRad @SpendingAlpha @rallamee @rwyeh @mshunshin @ProfDFrancis @venkmurthy @ajaykirtane @drjohnm @EJSMD FWIW, it can be done. Incredibly & wisely this NCI trial increased sample size by 73% (!) based on early results.
RT @drchrysopoulo: Landmark #TAILORx study definitively shows chemo may be spared in about 70% of hormone +ve, HER2 -ve, node-neg #BreastCa…
RT @drchrysopoulo: Landmark #TAILORx study definitively shows chemo may be spared in about 70% of hormone +ve, HER2 -ve, node-neg #BreastCa…
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
This gene expression test could change the approach to the treatment of breast cancer https://t.co/70YfeJwPNm
The power of translational research and molecular biomarkers. New Standard of care in breast cancer management. https://t.co/HBJLxKcztt
RT @ChristianeLoell: Seit Jahren gibt es Streit um die Gentests bei Brustkrebs, nun gibt es mehr Daten dazu. Achtung: Dies ist kein Werbetw…
RT @TracyDixonSalaz: Wish we knew this for severe, uncontrolled epilepsy too. @LGS_Foundation https://t.co/DoUCrc7WaU
Many women with breast cancer may not need chemo. The Oncotype DX gene assay can help determine whether a person is spared the devastating effects of chemo. The study is found in the NEJM. https://t.co/EdmkIL5T8A https://t.co/NRy1ZgEnmU
RT @GenomicHealth: .@NEJM publication on the long-awaited results of the #TAILORx study of #Oncotype DX, the largest ever breast cancer tre…
RT @GenomicHealth: .@NEJM publication on the long-awaited results of the #TAILORx study of #Oncotype DX, the largest ever breast cancer tre…
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer | @NEJM #genome #PrecisionMedicine #nextgen https://t.co/uclqGUYP9j
New finding: those diagnosed with early-stage, with HER-2 positive breast cancer might benefit from hormone therapy and skip chemotherapy, that can have long-term consequences. https://t.co/T1bnRhFlx4
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
Adjuvant #Chemotherapy Guided by a 21-#GeneExpression Assay in #BreastCancer @NEJM @ASCO @theNCI https://t.co/HBRLRR42ik
No need for quemotherapy HR positive, Her 2 negative, axillary nodule negative, above 50 years old breast cancer , https://t.co/EJRgoeEAiu
Big news that impacts many patients. Still some nuance for women <50 with scores between 21 and 25. #LCI #LCIywbp https://t.co/lCSjb5ETK9
American Med business https://t.co/06LKq5jukc
Novo estudo na ASCO 2018 sugere que 70% das mulheres com câncer de mama localizado não requerem quimioterapia... https://t.co/GGjmceMYH7 https://t.co/wY4ERn0rZE
Thx @NEJM for simultaneously publishing this important practice changing trial presented at #ASCO18 plenary session. @UTSWIMchief @UTSWIMJW https://t.co/dIDGTw1sX3
RT @IlindelatorreMD: La quimioterapia adyuvante guiada por un ensayo de expresión de 21 genes en el cáncer de mama | NEJM https://t.co/VsAc…
RT @drzoewinters: https://t.co/YVfB8QgGBO The future is personalised to individual women with #breastcancer ER positive LN negative https:/…
RT @breasthealthmd: Women with node-negative breast cancer with intermediate risk Oncotype dx scores can safely avoid chemotherapy. https:/…
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
全体としてはQOLの向上が期待できる成果だが、誤って解釈されると必要な治療を受けない人が増える恐れもあるように思う。 https://t.co/YbTNB2ENrw
RT @williaminboston: How to refine chemotherapy benefit and recurrence risk in hormone receptor-positive breast cancer patients? The TAILOR…
元論文と思われるのはこちら。 "Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer" https://t.co/17Oc65guxD https://t.co/vvcbgmpjp2
RT @HenryKuerer: MORE info: Chemotherapy benefit for invasive disease–free survival varied with the combination of recurrence score and age…
RT @EladSharonMD: Great result for women with breast cancer! Very important trial sponsored by @theNCI! Specifically, @NCItreatment & @NC…
RT @GenomicHealth: .@NEJM publication on the long-awaited results of the #TAILORx study of #Oncotype DX, the largest ever breast cancer tre…
La quimioterapia adyuvante guiada por un ensayo de expresión de 21 genes en el cáncer de mama | NEJM https://t.co/VsAc9YtteQ
New and exciting research for #breastcancer #patients. Always important to do your #research and consult with your #oncologist @NEJM https://t.co/fvrDxO30go
Wish we knew this for severe, uncontrolled epilepsy too. @LGS_Foundation https://t.co/DoUCrc7WaU
RT @DrTashaG: Results of TAILORx study will be practice changing! Patients with ER positive, Her2 negative, node negative and a mid-range 2…
RT @DrTashaG: Results of TAILORx study will be practice changing! Patients with ER positive, Her2 negative, node negative and a mid-range 2…
RT @rschilsky: Yup. Well validated diagnostics save money and improve outcomes but are under-valued by our healthcare system! https://t.co/…
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. https://t.co/lUuFKgaUxW
RT @rschilsky: Yup. Well validated diagnostics save money and improve outcomes but are under-valued by our healthcare system! https://t.co/…
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
RT @drchrysopoulo: Landmark #TAILORx study definitively shows chemo may be spared in about 70% of hormone +ve, HER2 -ve, node-neg #BreastCa…
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
RT @rschilsky: Yup. Well validated diagnostics save money and improve outcomes but are under-valued by our healthcare system! https://t.co/…
Yup. Well validated diagnostics save money and improve outcomes but are under-valued by our healthcare system! https://t.co/O8a0dwOPty
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
Live on https://t.co/OxOLbLb0ww, you can hear #JeffAbrams, head of @NCICTEP_ClinRes, talking about the @theNCI sponsored TAILORx trial! Or, read about it in @NEJM now: https://t.co/usimceapSB. Great work sponsored by @theNCI and presented @ASCO!
@NEJM stdy that randomized #BCSM pts (hormone recep+, HER2-, axillary-node-) to endocrine (A) or chemoendocrine (B) Rx based on #OncotypeDX score found: A is not inferior to B (endpoint: invasiveDFS). @VinayPrasadMD @oncology_bg thoughts? Tweetorial time?
Very good news -- many women will be spared adjuvant chemotherapy. https://t.co/4OgEDLdkU9
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer https://t.co/IdapXbxHqr https://t.co/7AbzkWel8P
RT @drzoewinters: https://t.co/YVfB8QgGBO The future is personalised to individual women with #breastcancer ER positive LN negative https:/…
RT @GenomicHealth: .@NEJM publication on the long-awaited results of the #TAILORx study of #Oncotype DX, the largest ever breast cancer tre…
https://t.co/YVfB8QgGBO The future is personalised to individual women with #breastcancer ER positive LN negative https://t.co/b6019k519z
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
RT @GenomicHealth: .@NEJM publication on the long-awaited results of the #TAILORx study of #Oncotype DX, the largest ever breast cancer tre…
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
Importancia de HER2 y de receptores de cáncer de mama para definir mejor estrategia terapéutica https://t.co/rVgN3ePaXm
RT @JJRiosBlanco: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer | NEJM https://t.co/jdG5TwGx5P
RT @skathire: @VinayPrasadMD what's your take on this RCT of gene-expression test guided treatment for breast cancer? Thx #not_trolling #…
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
RT @KirstinOConnor_: BIG NEWS for the fight against breast cancer. No more Chemo for about 70% of women with early stage cancer. Study—-> https://t.co/Kg8QIhjuaT https://t.co/uYQxJJ0czR
Great result for women with breast cancer! Very important trial sponsored by @theNCI! Specifically, @NCItreatment & @NCICTEP_ClinRes along with academic partners! https://t.co/YcnIYQR76V
RT @mytripleneglife: If anyone would like to read the article #BCCIre #bccww @bccire 👇🏽 https://t.co/ZvJ1WXVlXC
RT @mytripleneglife: If anyone would like to read the article #BCCIre #bccww @bccire 👇🏽 https://t.co/ZvJ1WXVlXC
Exciting data from @ASCO #chemo #metup #asco18 #bcvision #BreastCancer #BreastCancerawareness https://t.co/S5Tmoqw7iw
RT @CDNCancerTrials: Great news for #breastcancer patients around the world! Many women with early-stage forms of the disease can forego ch…
RT @NCICCR_WMB: “Endocrine therapy was noninferior to chemoendocrine therapy” in women with #breastcancer recurrence score 11-25 — results…
“Endocrine therapy was noninferior to chemoendocrine therapy” in women with #breastcancer recurrence score 11-25 — results presented @ASCO #ASCO18 https://t.co/2mDFoOx0BY
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
How to refine chemotherapy benefit and recurrence risk in hormone receptor-positive breast cancer patients? The TAILORx study is out and made the news from @ASCO. Your genes matter. #CancerResearch #FightCancer https://t.co/ArF218RtDU
RT @DrTashaG: Results of TAILORx study will be practice changing! Patients with ER positive, Her2 negative, node negative and a mid-range 2…
RT @mytripleneglife: If anyone would like to read the article #BCCIre #bccww @bccire 👇🏽 https://t.co/ZvJ1WXVlXC
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
RT @DrTashaG: Results of TAILORx study will be practice changing! Patients with ER positive, Her2 negative, node negative and a mid-range 2…
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
RT @GenomicHealth: .@NEJM publication on the long-awaited results of the #TAILORx study of #Oncotype DX, the largest ever breast cancer tre…
RT @GenomicHealth: .@NEJM publication on the long-awaited results of the #TAILORx study of #Oncotype DX, the largest ever breast cancer tre…
RT @protoninfo: Good news for #BreastCancer patients: 60,000 per year can safely skip chemo, study suggests https://t.co/J2NVVrxJWy
Big deal! We've heavily over-treating a lot of breast cancers. Fingers crossed these results get quickly incorporated into regular clinical decision making. https://t.co/WlLOzkmNQ1
RT @YvanButera: Big step! https://t.co/rcwTVJt2PP
Big step! https://t.co/rcwTVJt2PP
RT @DrTashaG: Results of TAILORx study will be practice changing! Patients with ER positive, Her2 negative, node negative and a mid-range 2…
TAILORx results https://t.co/ufA9RJj7CX
21-Gene panel useful for predicting whether a patients need chemo at all in early-stage brest cancer #personalizedmedicine https://t.co/Ct1Cmk8asv
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
@ren_rtd そだねー。。これもアジュバンドのケモがいるかどうかみたいたけどね。。 元ネタこれみたい。 https://t.co/vrgWIYOKeW
RT @protoninfo: Good news for #BreastCancer patients: 60,000 per year can safely skip chemo, study suggests https://t.co/J2NVVrxJWy
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer | NEJM https://t.co/l8Yy7Cks7e
RT @CDNCancerTrials: Great news for #breastcancer patients around the world! Many women with early-stage forms of the disease can forego ch…
1 Prospective, randomized trial, 6711, ER+, HER2-, LN -, breast CA pts and recurrence score, 11-25, endocrine therapy=to chemo! 2 Rate of 9-year distant recurrence ~5%, irrespective of chemo use. 3 Chemo benefit in women <50, at least partly antiestrog
The authors say that the genetic assay could identify up to 85% of women with early breast cancer who could avoid chemotherapy, particularly those who are older than age 50 #breastcancer #cancer #CancerResearch https://t.co/X9qfzygYfM
RT @NEJM: Original Article: Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer (TAILORx) https://t.co/rQ4b15lb0s #…